Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Revenue	$ 15,622	$ 11,698	$ 69,429
Operating expenses:
Research and development	35,147	42,589	37,569
Selling, general and administrative	29,431	24,909	23,356
Intangible impairment charge	23,200
Change in contingent consideration liability	(5,800)	2,600	(4,600)
Total operating expenses	81,978	70,098	56,325
Operating (loss) income	(66,356)	(58,400)	13,104
Other (expense) income:
Interest (expense) income and other income, net	(2,933)	(4,285)	(527)
Total other (expense) income	(2,933)	(4,285)	(527)
(Loss) income before income tax (expense) benefit	(69,289)	(62,685)	12,577
Income tax benefit (expense)	1,632	11,672	(1,844)
Net (loss) income	(67,657)	(51,013)	10,733
Net loss attributable to noncontrolling interests			(73)
Net (loss) income attributable to Progenics	$ (67,657)	$ (51,013)	$ 10,806
Net (loss) income per share attributable to Progenics - basic (in dollars per share)	$ (0.87)	$ (0.73)	$ 0.15
Weighted-average shares - basic (in shares)	77,890	70,284	70,003
Net (loss) income per share attributable to Progenics - diluted (in dollars per share)	$ (0.87)	$ (0.73)	$ 0.15
Weighted-average shares - diluted (in shares)	77,890	70,284	70,155
Royalty [Member]
Revenue:
Revenue	$ 14,908	$ 10,965	$ 10,295
Product and Service, Other [Member]
Revenue:
Revenue	$ 714	$ 733	$ 59,134